Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms
ConclusionThis study reports that nelarabine with vorinostat can promote cytotoxicity in nelarabine-resistant leukemia cells through epigenetic mechanisms. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 26, 2021 Category: Cancer & Oncology Source Type: research

Population pharmacokinetic and exposure –response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma
ConclusionsThe PPK model adequately described the data and was appropriate for determining exposures for exposure –response analyses. There were no clinically relevant differences in elotuzumab exposures between Pd and Ld backbones. In ELOQUENT-3, increasing elotuzumab daily Cavg prolonged PFS without increasing grade 3  + AEs. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 26, 2021 Category: Cancer & Oncology Source Type: research

Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis
AbstractObjectiveAnti-programmed cell death-1 and programmed cell death ligand-1 (PD-1/PD-L1) inhibitors have been proved to have a significant clinical efficacy in the treatment of non-small cell lung cancer (NSCLC). Many studies have demonstrated that immune-related adverse events (irAEs) are significantly correlated with clinical efficacy, but the results are not consistent. This meta-analysis aimed to evaluate the associations between irAEs and efficacy.MethodsComprehensive searches were conducted on PubMed and EMBASE database. The HR and 95% CI were used to assess the associations between immune-related adverse events...
Source: Cancer Chemotherapy and Pharmacology - November 25, 2021 Category: Cancer & Oncology Source Type: research

A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib
ConclusionThe successful modeling exercise of erdafitinib preclinical data showed how translational PK-PD modeling might be a tool to help to inform the choice of the doses in FIH studies. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 17, 2021 Category: Cancer & Oncology Source Type: research

A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer
ConclusionsThe JAK1/2 and TBK1 inhibitor momelotinib in combination with erlotinib did not appear to enhance benefit over the historical data of erlotinib monotherapy in patients withEGFR-mutated NSCLC.ClinicalTrials.gov identifierNCT02206763. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 13, 2021 Category: Cancer & Oncology Source Type: research

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose –escalation phase 1 trial
ConclusionsDostarlimab demonstrated consistent and predictable PK and associated PDy. The observed safety profile was acceptable and characteristic of the anti-PD-1 drug class.Trial registration: ClinicalTrials.gov, NCT02715284. Registration date: March 9, 2016. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 8, 2021 Category: Cancer & Oncology Source Type: research

Integrated exposure –response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer
ConclusionsThe relationships evidenced in this integrated E –R analysis support a favorable benefit-risk profile for lurbinectedin 3.2 mg/m2 q3wk.Trial registrationClinicaltrials.gov: NCT02454972; registered May 27, 2015. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 5, 2021 Category: Cancer & Oncology Source Type: research

The use of vitamin E in preventing taxane-induced peripheral neuropathy
ConclusionOur study did not demonstrate a protective role of vitamin E in decreasing the incidence of CIPN in patients receiving taxane-based chemotherapy. However, the recovery from CIPN was much better as compared to the control arm, which may indicate a role for vitamin E in decreasing the duration and severity of CIPN. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 23, 2021 Category: Cancer & Oncology Source Type: research

Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib
ConclusionIpatasertib exhibited rapid absorption and was dose-proportional over a broad dose range. Ipatasertib appeared to be a moderate CYP3A inhibitor when administered at 600  mg and could be administered with or without food in clinical studies.Trail registrationNCT01090960 (registered March 23, 2010); NCT02536391 (registered August 31, 2015). (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 23, 2021 Category: Cancer & Oncology Source Type: research

A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies
ConclusionV and AC can be safely combined. Activity was observed in patients with metastatic breast cancer. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 20, 2021 Category: Cancer & Oncology Source Type: research

Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury
AbstractPurposeHigh-dose methotrexate (HDMTX)-associated acute kidney injury with delayed MTX clearance has been linked to an excess in MTX-induced toxicities. Glucarpidase is a recombinant enzyme that rapidly hydrolyzes MTX into non-toxic metabolites. The recommended dose of glucarpidase is 50 U/kg, which has never been formally established in a dose finding study in humans. Few case reports, mostly in children, suggest that lower doses of glucarpidase might be equally effective in lowering MTX levels.MethodsSeven patients with toxic MTX plasma concentrations following HDMTX therapy were treated with half-dose glucarpidas...
Source: Cancer Chemotherapy and Pharmacology - October 20, 2021 Category: Cancer & Oncology Source Type: research

Retraction Note to: Linc ‑ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR‑124/PTBP1/PKM2 axis
(Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 18, 2021 Category: Cancer & Oncology Source Type: research

Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6 –Cyclin D–Rb pathway
ConclusionsOur pre-clinical evidence provides a rationale of initializing clinical trial of investigating the efficacy of abemaciclib in combination with doxorubicin in osteosarcoma patients. Our work also highlights the therapeutic value of CDK4/6 inhibition in osteosarcoma with proper function of Rb. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 16, 2021 Category: Cancer & Oncology Source Type: research

Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case –control study
ConclusionThe administration of immune checkpoint inhibitors in non-small-cell lung cancer patients with a history of idiopathic interstitial pneumonia might be a viable treatment option and have clinical benefits. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 14, 2021 Category: Cancer & Oncology Source Type: research

Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis
ConclusionLenvatinib treatment should be avoided in patients with Vp4 with a high degree of portal trunk occlusion because of concerns about decreased portal blood flow. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 10, 2021 Category: Cancer & Oncology Source Type: research

Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer
ConclusionPF-06881894 as a single 3- or 6-mg dose prior to definitive surgery, or multiple 6-mg/cycle doses postoperatively, with/without myelosuppressive chemotherapy, was consistent with the clinical pharmacology and safety profile of reference pegfilgrastim.Trial registrationOctober 2017. ClinicalTrials.gov Identifier: NCT02650193. EudraCT Number: 2015-002057-35. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 7, 2021 Category: Cancer & Oncology Source Type: research

EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer
ConclusionExosomal delivery of miR-1915-3p can improve the chemotherapeutic efficacy of oxaliplatin in CRC cells by suppressing the EMT-promoting oncogenes PFKFB3 and USP2. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 2, 2021 Category: Cancer & Oncology Source Type: research

Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck
In this study, we looked for whether treatment-induced rash predicts treatment efficacy in patients with recurrent/metastatic HNSCC treated with Cetuximab and chemotherapy.MethodsPatients who were treated with platinum-based chemotherapy and cetuximab for the first line treatment of recurrent/metastatic HNSCC were recruited. Presence of rash, hypomagnesemia, hypopotassemia, anemia, neutropenia, thrombocytopenia during treatment and treatment response, date of progression, date of last visit and death were recorded.ResultsA total of 138 patients ’ data were available for analysis. Any grade of rash was detected in 57 ...
Source: Cancer Chemotherapy and Pharmacology - October 1, 2021 Category: Cancer & Oncology Source Type: research

Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease
AbstractPurposeCytotoxic chemotherapy-induced lung injury is a fatal complication in patients with lung cancer and interstitial lung disease (ILD). We aimed to evaluate the association between hyperglycemia and this form of lung injury in patients with lung cancer concomitant with ILD.MethodsFrom 1147 patients with advanced lung cancer, we retrospectively enrolled 98 patients with ILD whose hemoglobin A1c (HbA1c) levels were measured, and investigated the association between HbA1c levels and cytotoxic chemotherapy-induced lung injury. In 73 patients whose serum samples were retained, we measured serum levels of advanced gl...
Source: Cancer Chemotherapy and Pharmacology - October 1, 2021 Category: Cancer & Oncology Source Type: research

Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells
ConclusionProscillaridin A produces anticancer and epigenetic effects in the low nanomolar range and its combination with decitabine warrants further investigation for the treatment of eRMS. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 1, 2021 Category: Cancer & Oncology Source Type: research

A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjects
ConclusionsThis study demonstrated the safety and tolerability of ABP 980 and pertuzumab admixture in a single infusion bag. The safety profiles and pharmacokinetic parameters of ABP 980 and pertuzumab were consistent with what is known for trastuzumab RP and pertuzumab.Clinical trial listingEudraCT 2018-002903-33. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 1, 2021 Category: Cancer & Oncology Source Type: research

Influence of FPGS, ABCC4, SLC29A1, and MTHFR genes on the pharmacogenomics of fluoropyrimidines in patients with gastrointestinal cancer from the Brazilian Amazon
ConclusionFour polymorphisms of theABCC4,FPGS,SLC29A1, andMTHFR genes are likely to be potential predictive biomarkers for precision medicine in fluoropyrimidine-based treatments in the population of the Brazilian Amazon, which is constituted by a unique genetic background. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 1, 2021 Category: Cancer & Oncology Source Type: research

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
AbstractPurposeThe purpose of this study is to characterize niraparib pharmacokinetics (PK) and safety in patients with normal hepatic function (NHF) versus moderate hepatic impairment (MHI).MethodsPatients with advanced solid tumors were stratified by NHF or MHI (National Cancer Institute-Organ Dysfunction Working Group criteria [bilirubin  >  1.5–3 × upper limit of normal and any aspartate aminotransferase elevation]). In the PK phase, all patients received one 300 mg dose of niraparib. In the extension phase, patients with MHI received niraparib 200 mg daily; patients...
Source: Cancer Chemotherapy and Pharmacology - October 1, 2021 Category: Cancer & Oncology Source Type: research

A systematic review of inter-individual differences in the DNA repair processes involved in melphalan monoadduct repair in relation to treatment outcomes
ConclusionIt appears that inherited germline differences in monoadduct repair genes may be a risk factor for poor outcomes. However, the diversity of study design, patient cohorts, genes assessed and lack of replication, preclude any meta-analysis. Further prospective studies are required to validate these findings. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 1, 2021 Category: Cancer & Oncology Source Type: research

Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement
AbstractRelapse at the central nervous system (CNS) in acute myeloid leukemia (AML) carries a dismal prognosis. Treatment options are limited to intrathecal therapy, high-dose cytarabine, high-dose methotrexate, and radiotherapy. Novel strategies are needed. Venetoclax has recently been approved by the FDA, in combination with hypomethylating agents or low-dose cytarabine, for elderly adults or patients ineligible for intensive chemotherapy affected by AML. However, little is known on its efficacy in patients with leptomeningeal involvement. Here, we present a case of a 52-year-old patient affected by AML relapsed at CNS a...
Source: Cancer Chemotherapy and Pharmacology - September 29, 2021 Category: Cancer & Oncology Source Type: research

Population pharmacokinetic analysis of crizotinib in children with progressive/recurrent high-grade and diffuse intrinsic pontine gliomas
This study aimed to characterize the pharmacokinetics of crizotinib in this population and identify significant covariates.MethodsPatients (N = 36, age range 2.9–21.3 years) were treated orally once or twice-daily with 100–215 mg/m2 crizotinib and 50 –65 mg/m2 dasatinib. Pharmacokinetic studies were performed for crizotinib alone after the first dose and at steady state, and for the drug combination at steady state. Crizotinib plasma concentrations were measured using a validated LC –MS/MS method. Population modeling was performed (Monolix) and the impact of factors incl...
Source: Cancer Chemotherapy and Pharmacology - September 29, 2021 Category: Cancer & Oncology Source Type: research

Correction to: Population pharmacokinetic and exploratory exposure –response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
(Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - September 24, 2021 Category: Cancer & Oncology Source Type: research

Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission
ConclusionsA robust population PK model was built and qualified for entrectinib and M5, describing linear PK for both entities. This model was used to support the ROZLYTREK® new drug application. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - September 18, 2021 Category: Cancer & Oncology Source Type: research

Megestrol acetate is a specific inducer of CYP3A4 mediated by human pregnane X receptor
ConclusionThe results suggest that megestrol acetate is a specific inducer of CYP3A4 mediated by hPXR and therefore has the potential to cause drug interactions, especially in the co-administration with drugs that are substrates of CYP3A4. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - September 15, 2021 Category: Cancer & Oncology Source Type: research

Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results
ConclusionPhenotyping based on measuring plasma [U] before a dialysis sessions in ESRD patients is associated with an unacceptable high rate of false positives. The optimal strategy for the identification of patients with DPD deficiency in this population would be the monitor the [UH2]:[U] ratio, which remains unaffected. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - September 13, 2021 Category: Cancer & Oncology Source Type: research

The related miRNAs involved in doxorubicin resistance or sensitivity of various cancers: an update
AbstractDoxorubicin (DOX) is an effective chemotherapy agent against a wide variety of tumors. However, intrinsic or acquired resistance diminishes the sensitivity of cancer cells to DOX, which leads to a cancer relapse and treatment failure. Resolutions to this challenge includes identification of the molecular pathways underlying DOX sensitivity/resistance and the development of innovative techniques to boost DOX sensitivity. DOX is classified as a Topoisomerase II poison, which is cytotoxic to rapidly dividing tumor cells. Molecular mechanisms responsible for DOX resistance include effective DNA repair and resumption of...
Source: Cancer Chemotherapy and Pharmacology - September 12, 2021 Category: Cancer & Oncology Source Type: research

Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice —a prospective single-center trial
AbstractPurposeKnowledge on Ruxolitinib exposure in patients with graft versus host disease (GvHD) is scarce. The purpose of this prospective study was to analyze Ruxolitinib concentrations of GvHD patients and to investigate effects of CYP3A4 and CYP2C9 inhibitors and other covariates as well as concentration-dependent effects.Methods262 blood samples of 29 patients with acute or chronic GvHD who were administered Ruxolitinib during clinical routine were analyzed. A population pharmacokinetic model obtained from myelofibrosis patients was adapted to our population and was used to identify relevant pharmacokinetic properti...
Source: Cancer Chemotherapy and Pharmacology - September 10, 2021 Category: Cancer & Oncology Source Type: research

Human placental extract ameliorates methotrexate-induced hepatotoxicity in rats via regulating antioxidative and anti-inflammatory responses
AbstractPurposeMethotrexate (MTX) induces hepatotoxicity, limiting its clinical efficacy as a widely known chemotherapy drug. In the current study, we examined the protective effect of human placenta extract (HPE) against MTX-induced liver damage in rats, as well as its ability to regulate antioxidative and anti-inflammatory liver responses.MethodsMale rats were orally administered MTX at a daily dose of 5  mg/kg-body-weight in the presence or absence of HPE (10.08 mg/kg) for 2 weeks. We measured the biological effects of MTX and HPE on the levels of liver enzymes, lipid profile, lipid peroxidation, oxi...
Source: Cancer Chemotherapy and Pharmacology - September 10, 2021 Category: Cancer & Oncology Source Type: research

Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach
ConclusionsThese results suggest that fedratinib has minimal impact on the exposure of P-gp, BCRP, OATP1B1/1B3, OCT2, and MATE1/2-K substrates. Since renal clearance of metformin was decreased in the presence of fedratinib, caution should be exercised in using coadministered drugs that are renally excreted via OCT2 and MATEs.Trial registrationClinicaltrials.gov NCT04231435 on January 18, 2020. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - September 3, 2021 Category: Cancer & Oncology Source Type: research

Zileuton inhibits arachidonate-5-lipoxygenase to exert antitumor effects in preclinical cervical cancer models
ConclusionsOur work demonstrates that the ALOX5-5-HETE axis is activated in cervical cancer, with important roles in growth and survival, and this can be therapeutically targeted by zileuton. Our findings also provide preclinical evidence to assess the efficacy of zileuton in cervical cancer in clinical settings. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - September 3, 2021 Category: Cancer & Oncology Source Type: research

Comment on “Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase”
(Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - September 1, 2021 Category: Cancer & Oncology Source Type: research

Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment
AbstractCancer is the second leading cause of death globally. Chemotherapy and radiation therapy and other medications are employed to treat various types of cancer. However, each treatment has its own set of side effects, owing to its low specificity. As a result, there is an urgent need for newer therapeutics that do not disrupt healthy cells ’ normal functioning. Depriving nutrient or non/semi-essential amino acids to which cancerous cells are auxotrophic remains one such promising anticancer strategy.l-Arginine (Arg) is a semi-essential vital amino acid involved in versatile metabolic processes, signaling pathway...
Source: Cancer Chemotherapy and Pharmacology - August 19, 2021 Category: Cancer & Oncology Source Type: research

Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials
ConclusionNo covariate had a clinically meaningful impact on bemarituzumab exposure. These results indicate that dose adjustment of bemarituzumab is not necessary, based on the aforementioned covariates, for a future phase 3 trial in gastric and gastroesophageal junction adenocarcinoma population with FGFR2b overexpression  in combination with mFOLFOX6. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - August 12, 2021 Category: Cancer & Oncology Source Type: research

A phase 1, open-label, drug –drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors
ConclusionRucaparib 600  mg BID weakly increased the plasma exposure to rosuvastatin or oral contraceptives. Rucaparib safety profile when coadministered with rosuvastatin or oral contraceptives was consistent with that of rucaparib monotherapy. Dose adjustments of rosuvastatin and oral contraceptives are not necessary wh en coadministered with rucaparib.ClinicalTrials.gov NCT03954366;Date of registration May 17, 2019. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - August 9, 2021 Category: Cancer & Oncology Source Type: research

Minimal PK/PD model for simultaneous description of the maximal tolerated dose and metronomic treatment outcomes in mouse tumor models
ConclusionOur results demonstrate that the proposed model presents a minimal yet efficient tool for modeling outcomes in different treatment regimens in mice. We hope that this model has the potential for use in clinical practice in the development of patient-specific chemotherapy scheduling protocols based on observed treatment response. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - August 5, 2021 Category: Cancer & Oncology Source Type: research

Correction to: Anticancer potential of metformin: focusing on gastrointestinal cancers
(Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - August 2, 2021 Category: Cancer & Oncology Source Type: research

Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients
ConclusionComedications may be the cause for this inter-occasion variation in bioactivation of cyclophosphamide and the ensuing phenoconversion may account for the conflicting reports in the literature about the relationship betweenCYP2C19 genotype and CP bioactivation pharmacokinetics. Trial registration ANZCTR363222 (6/11/2012, retrospectively registered). (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - July 27, 2021 Category: Cancer & Oncology Source Type: research

Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokinetic –pharmacodynamic real-life study
ConclusionIn this study, exposure-efficacy and tolerance analysis highlighted the interest of therapeutic drug monitoring to optimize therapeutic management inBRAFV600mut metastatic melanoma patients based on trough concentrations of dabrafenib and trametinib. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - July 27, 2021 Category: Cancer & Oncology Source Type: research

A triple combination gemcitabine  + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis
ConclusionThe gemcitabine plus romidepsin  + cisplatin regimen was highly efficacious in controlling TNBC tumor development, recurrence, and metastasis in animals. The combination regimen should be poised for efficient translation into clinical trials for controlling the recurrence and metastasis, ultimately contributing to reducing mor tality and improving TNBC patients’ quality of life. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - July 27, 2021 Category: Cancer & Oncology Source Type: research

Predictive value of ERCC2, ABCC2 and MMP2 of response and long-term survival in locally advanced head and neck cancer patients treated with chemoradiotherapy
ConclusionsOur findings highlight the potential usefulness of SNPs in different genes involved in drug metabolism and repair DNA to predict the response and survival to CRT.ABCC2 is a potential predictor of OS in patients with HNC. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - July 26, 2021 Category: Cancer & Oncology Source Type: research

Antitumor efficacy of CHMFL-KIT-110 solid dispersion in mouse xenograft models of human gastrointestinal stromal tumors
ConclusionsIn comparison with the HPMC formulation, both improved PK and PD characteristics of the solid dispersion formulation of CHMFL-KIT-110 were observed in in vivo animal experiments. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - July 26, 2021 Category: Cancer & Oncology Source Type: research

Prevalence of drug –drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management
AbstractBackgroundThe risk of drug –drug interactions (DDI) has become a major issue in cancer patients. However, data in sarcoma patients are scarce. We aimed to evaluate the frequency and the factors associated with DDI with antitumor treatments, and to evaluate the impact of a pharmacist evaluation before anticancer treatment.Patients and methodsWe performed a retrospective review of consecutive sarcoma patients starting chemotherapy (CT) or Tyrosine kinase inhibitor (TKI). A pharmacist performed medication reconciliation and established an early toxicity risk assessment. Potential DDI with antitumor drugs were id...
Source: Cancer Chemotherapy and Pharmacology - July 24, 2021 Category: Cancer & Oncology Source Type: research

Effect of carboplatin dose capping on survival in recurrent breast, ovary and head and neck cancers: a single institutional retrospective study
AbstractIntroductionCarboplatin based regimens are an integral part of chemotherapy regimens for recurrent head and neck cancers (rHNC), triple negative breast cancers (rTNBC) and ovarian cancers (rOC). Dose reduction/capping of carboplatin remains a controversial aspect of such regimens in patients with moderate creatinine clearance (50  ml/min to 125 ml/min), especially in resource limited setting. The authors, therefore, looked into the magnitude of difference in outcome this makes in the above mentioned subsites.MethodsThis single institutional retrospective study was performed with a total of 120 patients di...
Source: Cancer Chemotherapy and Pharmacology - July 23, 2021 Category: Cancer & Oncology Source Type: research

Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug –drug interactions with oral targeted therapy
ConclusionThis is the first prospective study evaluating the relevance of proactive BPMH by pharmacist with contact to the community pharmacy during the inclusion step of a clinical trial to ensure the efficacy and safety of the investigated drug. This investigation was thus able to highlight the statistically significant impact of these DDI on palbociclib plasma concentration variation during the clinical trial.Trial registrationClinicaltrials.gov identifier NCT04025541. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - July 20, 2021 Category: Cancer & Oncology Source Type: research

Correction to: Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia
(Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - July 18, 2021 Category: Cancer & Oncology Source Type: research